DiaSorin commercialized the first Vitamin D assay more than 25 years ago and have maintained its pioneering spirit through the process of continuous improvement of Vitamin D assays.
The LIAISON® 25 OH Vitamin D TOTAL Assay uses chemiluminescent immunoassay (CLIA) technology for the quantitative determination of 25-hydroxyvitamin D and other hydroxylated vitamin D metabolites in human serum, EDTA-plasma or lithium heparin plasma to be used in the assessment of vitamin D sufficiency using the LIAISON® Analyzer family. Assay results should be used in conjunction with other clinical or laboratory data to assist the clinician in making individual patient management decisions in an adult population.
The DiaSorin LIAISON® XL 1,25 Dihydroxyvitamin D is an in vitro chemiluminescent immunoassay (CLIA) intended for the quantitative determination of 1,25 dihydroxyvitamin D (1,25(OH)2D) in serum, EDTA and Lithium Heparin plasma. Assay results should be used in conjunction with other clinical and laboratory data to assist the clinician in making individual patient management decisions in adult populations.
The test is to be performed on the LIAISON® XL Analyzer.
The role of Vitamin D in regulating circulating levels of Calcium and Phosphorous to ensure normal bone mineralization is well known. Emerging evidence correlates insufficient levels of Vitamin D to an increased risk of developing non skeletal pathologies such as cardiovascular disease, cancer, diabetes, autoimmune diseases and infectious diseases.
The diverse effects of Vitamin D are mediated by receptors that regulate hundreds of genes. Thus maintaining sufficient Vitamin D levels is key to maintaining good health. Although Vitamin D3 (cholecalciferol) can be synthesized in the skin upon exposure to ultraviolet-B (UVB) radiation, Vitamin D deficiency is common throughout the world with an estimated one billion people affected.